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LETTER TO THE EDITOR
Carboplatin and renal function in children
Sir - The advantage of carboplatin in tumours known to
demonstrate cisplatinum sensitivity is the prospect of reduced
nephro- and ototoxicity. Sleijfer et al. (1989), however, sug-
gested from data derived in adults receiving carboplatin at a
dose of 400 mg m-2 that significant reductions of GFR
occur. This is contrary to general clinical experience in
paediatric practice and a recent phase II study of carboplatin
in relapsed neuroblastoma undertaken by the United King-
dom Children's Cancer Study Group (UKCCSG) has provid-
ed further information on this issue.
Thirty-four patients with relapsed or resistant neuroblas-
toma were entered into a phase II study of carboplatin given
at a dose of 550 mg m-2 and infused over 1 h with no pre- or
post-hydration. Thirty patients were eligible for toxicity
assessment. A total of 82 courses of carboplatin were admin-
istered - 13 patients receiving four courses, 14 three courses,
25 two courses and 30 the first course. The intended dose
interval was 21 days, but the median interval was 29 days
because of time required for haematological recovery. All
patients had previously received cisplatinum. Renal function
assessment by 5tCr EDTA clearance was assessed before and
after two courses of treatment in 19 patients and before and
after four courses of treatment in nine patients. The median
change in GFR (expressed as percent difference from the
pre-treatment value) was + 1% (range - 35 to + 53) after
two courses and + 9% (range - 45 to + 43) after four
courses. Overall, 3/19 showed a >20% fall in GFR after
two courses (23, 27 and 35%) and 2/9 after four courses (21
and 45%). The absolute values for post-treatment GFR in
these two groups were 85, 98 and 71 ml min 1.73 m-2 (after
two courses) and 69 and 86 ml min 1.73 m-2 (after four
courses). There appeared to be no relationship to pre-treat-
ment GFR and no other identifiable factor influenced the
chance of a deterioration in renal function. Two children had
significant pre-treatment impairment of renal function, but
neither showed further serious deterioration with GFR
changing from 50 to 44 and 37 to 38 ml min 1.73 m-2 respec-
tively. No other child showed a final GFR<60 ml min 1.73
m-2 regardless of pre-treatment GFR.
As was expected from early studies in adults, pre-treatment
renal function had a significant effect on subsequent myelo-
suppression. The incidence of Grade 3 and 4 haematological
toxicity was substantially greater in patients with a pre-
treatment GFR<90, particularly with regard to neutropenia
(67% vs 38% for patients with GFR>90) and thrombocyto-
penia (84% vs 33%; P = 0.05) using data from courses one
and two combined. This resulted in a greater median delay
between treatments for the patients with reduced GFR. Four
of the 12 patients with GFR <90 had dose reductions
imposed for haematological toxicity after the first course
compared to none of the 14 with GFR>90.
A more recent report from adult patients receiving high
dose (1 g m-2) carboplatin demonstrated a transient, but
reversible effect on renal function (Hardy et al., 1990). Fur-
ther data are required to explore cumulative nephrotoxicity
in children, but this study suggests that there is little risk of
significant early deterioration in renal function in children
receiving carboplatin. The relationship of pre-treatment renal
impairment to subsequent myelosuppression supports the
concept that carboplatin dosage should be calculated on the
basis of renal function (Calvert et al., 1989).
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